

**For the longest-lasting gentlest relief of all Otrivine the leading nasal decongestant : the longest trial ...**

**Contributors**

Ciba Laboratories

**Publication/Creation**

[approximately 1964]

**Persistent URL**

<https://wellcomecollection.org/works/p2vhgb5q>

**License and attribution**

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome  
collection**

Wellcome Collection  
183 Euston Road  
London NW1 2BE UK  
T +44 (0)20 7611 8722  
E [library@wellcomecollection.org](mailto:library@wellcomecollection.org)  
<https://wellcomecollection.org>

## The longest trial

in the annals of British Justice  
was the Tichborne personation  
case which in all covered  
a period of 827 days.



To the Medical Profession

for the longest-lasting  
gentlest relief of all

**Otrivine<sup>®</sup>**

xylometazoline hydrochloride

the most widely prescribed  
nasal decongestant

clears nasal congestion in a few minutes

effective for up to eight hours

remarkable freedom from rebound hyperaemia

gentle even for infants

## Otrivine in Infants

Although acute rhinopharyngitis is commonly regarded as an unpleasant but as a rule harmless condition in small children and school children, the more serious consequences of the condition as far as infants are concerned should be appreciated. Marked impairment or total suppression of nasal breathing can arise from even slight congestion of the nasal mucosa during the early months of life, making swallowing a problem, with consequent difficulties in feeding. Moreover, nasal obstruction may lead to an increased danger of middle ear involvement.

Owing to the risk of local and systemic adverse reactions however, administration of

most nasal decongestants to infants is generally regarded as a particularly hazardous procedure requiring great care and skill to avoid over dosage. The special Otrivine Paediatric (0.05%) solution on the other hand has been found to be both effective and trouble-free when used in infants with nasal congestion. The unique metered dose dropper bottle prevents accidental overdosage, and since the vasoconstrictor action of Otrivine is not intense, gentle relief of congestion lasting for up to eight hours is achieved without accompanying local effects. Unlike ephedrine, effects on circulation, blood pressure and cardiac activity are not encountered following the use of Otrivine in the nose.

### Some quotations on the use of Otrivine in infants.

"It represents a useful decongestant effect for all purposes in early childhood . . . even in premature and cardiac infants no side effects whatsoever were observed<sup>1</sup>."

"The particularly striking feature of xylometazoline (Otrivine) solution was the absence of side effects even in children as young as two weeks<sup>2</sup>."

1. Schweiz. Med. Wschr. (1959) 89, 510

2. Gen. Pract. (1960) 21, 33

C I B A

the gentle nasal decongestant

## Otrivine<sup>®</sup>

Certain additional advantages single out Otrivine from other vasoconstrictors

### **No adverse effects on nasal mucosa or ciliary activity**

Otrivine solutions are well tolerated, and there have been no reports of adverse effects on the nasal mucosa or on ciliary activity.

### **Freedom from rebound congestion**

Widespread use of Otrivine has shown it to be remarkably free from hyperaemic rebound effects. The effective yet gentle vasoconstriction produced by Otrivine avoids undue local ischaemia and subsequent rebound vasodilatation and congestion.

### **Exceptionally prolonged effect**

Up to eight hours' duration of action. Twice daily applications only are necessary, and one application at bedtime will usually maintain a clear nasal airway for the whole night.

### **Unique metered dose dropper for infants**

A specially designed teat is fitted to the Paediatric solution (0.05%) dropper bottle which limits the volume of solution applied, thereby avoiding risk of overdosage.

### **Prescribing notes**

#### **Dosage**

One application by spray or two to three drops Otrivine 0.1% solution in each nostril two or three times daily. Children: 1-2 drops Otrivine Paediatric solution (0.05%) once or twice but not more than three times daily.

#### **Side effects and precautions.**

The use of Otrivine in sensitive subjects may result in tachycardia in rare cases. The prolonged use of vasoconstrictors is not recommended in chronic rhinitis.

#### **Basic NHS prices**

0.1% Nasal spray and drops ½ fl.oz 3s 4d.

Paediatric 0.05% drops 10 ml 3s od

Full information on request.

C I B A

<sup>®</sup> denotes registered trademark. Reg. user  
CIBA Laboratories Limited, Horsham, Sussex.

D947